Compare BridgeBio Pharma Inc (BBIO) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nucor Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Nucor Corporation trades at $272.98 (market cap $62.54B). The key difference: Nucor Corporation is far larger — about 3.8× BridgeBio Pharma Inc's market cap, and Nucor Corporation pays a 0.82% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NUE | |
|---|---|---|
Market Cap | $16.61B | $62.54B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $274.74 |
52-Week Low | $47.29 | $131.78 |
Enterprise Value | $18.16B | $66.95B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Nucor (NUE) trades at $272.63, up 0.23% on the day, with a bullish technical outlook supported by moving averages and strong resistance near $280. Recent Q2 2026 earnings beat expectations with EPS of $4.84 versus $4.46, driven by record steel shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections at $36.1B. The stock is near its consensus price target of $279.63, with analyst sentiment leaning bullish (59% buy ratings).
Outlook: Nucor benefits from resilient steel demand and operational efficiency, but faces risks from tariff policies and cyclical industry pressures. The current P/E of 21.76 is reasonable given earnings growth, though net margins have compressed from 2022 peaks. Investors should monitor Q3 2026 results against the $5.72 EPS estimate for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
